申联生物：股东UBI拟减持公司不超3%股份

Core Viewpoint - UBI, a shareholder holding 10.52% of Shenyuan Biological (688098), plans to reduce its stake due to funding needs for clinical trials and commercialization of its Alzheimer's peptide vaccine and related manufacturing base in China [1] Group 1: Shareholder Actions - UBI intends to reduce its holdings by up to 4.1064 million shares through centralized bidding, representing 1% of the total share capital [1] - Additionally, UBI plans to reduce its holdings by up to 8.2129 million shares through block trading, accounting for 2% of the total share capital [1]